Clinical Trial Protocol
Iranian Registry of Clinical Trials

16 Sep 2026

Comparative bioequivalence study of the Regorafenib 40 mg, tablet manufactured by Noavaran Daroui Kimia Company

Protocol summary

Study aim

Examining the bioequivalency of domestically produced Regorafenib tablet formulations with brand samples(Stivarga®)

Design

A single-group, not blinded, not randomized, bioequivalence clinical trial on 24 healthy volunteers.

Settings and conduct

Study place: Drug Applied Research Center affiliated to Tabriz University of Medical Science. The number of 24 volunteer in the age range of 18-60 years and the Body Mass Index range of 18-30, who are voluntarily selected through public notification. One tablet is taken fasting and blood is taken at 17 times point. Three week later, the process is repeated for the brand medicine

Participants/Inclusion and exclusion criteria

The weight range of participating candidates should be between 60-100 kg All candidates must be non-smokers Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (γ-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose Volunteers who have agreed to an informed consent form

Intervention groups

After taking a Regorafenib 40-mg tablet from domestic company, 3 milliliters of blood will be collected from the volunteer in 17 times intervals for 96 hours. Three week later, the process is repeated for a brand sample tablet. The drug concentration is measured in plasma

Main outcome variables

Studying the Drug pharmacokinetic parameters including measuring the plasma concentrations for brand and test products, determining the desired and important pharmacokinetic parameters in bioequivalence studies, AUCs, Tmax, Cmax, T1/2 and appropriate statistical analysis of the data

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20130313012810N24**
Registration date: **2024-01-22, 1402/11/02**
Registration timing: **prospective**

Last update: **2024-01-22, 1402/11/02**
Update count: **0**

Registration date

2024-01-22, 1402/11/02

Registrant information

Name

Hamed Hamishehkar

Name of organization / entity

Drug Applied Research Center, Tabriz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 41 1336 3311

Email address

hamishehkar.hamed@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-01-25, 1402/11/05

Expected recruitment end date

2024-01-26, 1402/11/06

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparative bioequivalence study of the Regorafenib 40 mg, tablet manufactured by Noavaran Daroui Kimia Company

Public title

Regorafenib tablet bioequivalence

Purpose

Other

Inclusion/Exclusion criteria

Inclusion criteria:

The weight range of participating candidates should be between 60-100 kg All candidates must be non-smokers Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (γ-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose. Volunteers who have agreed to an informed consent form. All candidates should not consume caffeine-containing drinks and chocolate during two days before the prescription, and this restriction must be followed until the last blood draw

Exclusion criteria:

History of allergic or adverse reaction to Pazopanib or any similar product Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg Smokers Individuals who donated whole blood or blood components within 2 months within 2 weeks prior to the first dose of the study product(s) Due to the possibility of QT prolongation complications, volunteers with a family history of heart diseases, especially rhythm disorders, are excluded from the study.

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

Bioequivalence

Groups that have been masked

No information

Sample size

Target sample size: **24**

Randomization (investigator's opinion)

N/A

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Crossover

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Tabriz University of Medical Sciences

Street address

Drug Applied Research Center, Daneshghah St.

City

Tabriz

Province

East Azarbaijan

Postal code

5165665811

Approval date

2024-01-14, 1402/10/24

Ethics committee reference number

IR.TBZMED.REC.1402.775

Health conditions studied

1

Description of health condition studied

Bioequivalence study in healthy volunteers

ICD-10 code

ICD-10 code description

Primary outcomes

1

Description

Plasma concentration of the drug

Timepoint

17 sampling time till 96 h

Method of measurement

Liquid Chromatography with tandem mass spectrometry (LC-MS-MS)

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: This study examines the bioequivalence of the Regorafenib tablet produced by a domestic company with a foreign brand sample. We have only one intervention group and there is no control

group. The intervention group, which includes healthy, fasting volunteers, will receive a single dose, 40 mg tablet manufactured by the pharmaceutical company Noavaran Daroui Kimia and Stivarga® brand, in two 96-hour periods with an interval of three week, on the day of the study. And in 17 different time periods up to 96 hours after taking the medicine, blood samples will be taken from the volunteers in the amount of 3 ml each time, that is, a total of 51 ml within 96hours. The training that will be given to the volunteers includes avoiding the consumption of drinks containing alcohol and xanthine and other interfering drugs in the prescription drug from 48 hours before the start of the study until the end of the study.

Category

Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Drug Applied Research Center, Tabriz University of Medical Sciences

Full name of responsible person

Hamed Hamishehkar

Street address

Drug Applied Research Center, Tabriz University of Medical Sciences,Daneshghah St., Tabriz, Iran

City

Tabriz

Province

East Azarbaijan

Postal code

51656-65811

Phone

+98 41 3336 3311

Email

hamishehkar.hamed@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kimia Noavaran Daroui

Full name of responsible person

Esmaeil Moazeni

Street address

No. 1462, Jalal-Al-Ahmad Highway, Karghar Shomali

City

Tehran

Province

Tehran

Postal code

1439955991

Phone

+98 21 8801 2946

Email

info@kimia-pharma.co

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Kimia Noavaran Daroui

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Hamed Hamishehkar

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Drug Applied Research Center, Tabriz University of Medical Sciences, Daneshghah St., Tabriz, Iran

City

Tabriz

Province

East Azarbaijan

Postal code

51656-65811

Phone

+98 41 3336 3181

Fax

+98 41 3336 3311

Email

hamishehkar.hamed@gmail.com

Web page address

http://darc.tbzmed.ac.ir/

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Hamed Hamishehkar

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work
Medical Pharmacy
Street address
Drug Applied Research Center, Tabriz University of Medical Sciences, Daneshghah St., Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
51656-65811
Phone
+98 41 3336 3181
Fax
+98 41 3336 3311
Email
hamishehkar.hamed@gmail.com
Web page address
http://darc.tbzmed.ac.ir/

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Hamed Hamishehkar
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Drug Applied Research Center, Tabriz University of Medical Sciences, Daneshghah St., Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
51656-65811
Phone
+98 41 3336 3181
Fax
+98 41 3336 3311
Email
hamishehkar.hamed@gmail.com
Web page address
http://darc.tbzmed.ac.ir/

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available